利妥昔单抗治疗威胁视力的难治性儿童Vogt-小柳-原田病。
Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease.
作者信息
Umran Raid M R, Shukur Zaid Y H
机构信息
a Department of Pediatrics , University of Kufa, College of Medicine, Al- Zahraa Teaching Hospital , Najaf , Iraq.
b Department of Physiology , University of Kufa, College of Medicine, Al Sader Teaching Hospital , Najaf , Iraq.
出版信息
Mod Rheumatol. 2018 Jan;28(1):197-199. doi: 10.3109/14397595.2015.1071234. Epub 2015 Aug 18.
Rituximab was trialed in a refractory Vogt-Koyanagi-Harada disease (VKH). A 10-year-old girl with panuveitis recalcitrant to treatment, including corticosteroids, was diagnosed with VKH 20 months later. Following rituximab at 0, 1, 6, and 18 months, response was favorable after the second dose, usual life activity resumed after the third dose (uveitis was inactivated and vision improved), and eyes stabilized 9 months after the fourth dose. Rituximab is effective in the treatment and long-term control of advanced, pediatric VKH.
利妥昔单抗在难治性葡萄膜大脑炎（VKH）中进行了试验。一名10岁女孩患有全葡萄膜炎，对包括皮质类固醇在内的治疗均无反应，20个月后被诊断为VKH。在第0、1、6和18个月使用利妥昔单抗后，第二剂后反应良好，第三剂后恢复了正常生活活动（葡萄膜炎得到控制且视力改善），第四剂后9个月眼睛状况稳定。利妥昔单抗在晚期儿童VKH的治疗和长期控制中有效。
Zotero 插件